An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date

References

• JunlénHR, PetersonS, KimbyE, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29(3):668–676. doi:10.1038/leu.2014.25125151959
   PubMed Web of Science ®Google Scholar
• LinkBK, FriedbergJW, TaylorMD, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–1208. doi:10.1200/JCO.2008.18.149519204203
   PubMed Web of Science ®Google Scholar
• SuredaA, ZhangMJ, DregerP, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733–1742. doi:10.1002/cncr.3126429424927
   PubMed Web of Science ®Google Scholar
• FedericoM, MdcB, MarcheselliL, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):e359–e367. doi:10.1016/S2352-3026(18)30090-530078408
   PubMed Web of Science ®Google Scholar
• BriceP, BastionY, LepageE, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2016;15(3):1110–1117. doi:10.1200/JCO.1997.15.3.1110
   Web of Science ®Google Scholar
• ArdeshnaK, SmithP, NortonA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522. doi:10.1016/S0140-6736(03)14110-412932382
   PubMed Web of Science ®Google Scholar
• MatasarMJ, LuminariS, BarrPM, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24(11):e1236. doi:10.1634/theoncologist.2019-013831346132
   PubMed Web of Science ®Google Scholar
• GribbenJG, FowlerN, MorschhauserF. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811. doi:10.1200/JCO.2014.59.536326195701
   PubMed Web of Science ®Google Scholar
• ChesonBD, MorschhauserF, MartinP. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(9):563–571. doi:10.1016/j.clml.2020.03.00932303486
   PubMed Web of Science ®Google Scholar
• FowlerNH, DavisRE, RawalS, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–1318. doi:10.1016/S1470-2045(14)70455-325439689
   PubMed Web of Science ®Google Scholar
• StratiP, JainP, JohnsonRJ, et al. Long term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood. 2021;137(8):1124–1129.32932518
   PubMed Web of Science ®Google Scholar
• MartinP, JungSH, PitcherB, et al. A Phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017;28(11):2806–2812. doi:10.1093/annonc/mdx49628945884
   PubMed Web of Science ®Google Scholar
• ZuccaE, RondeauS, VanazziA, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019;134(4):353–362. doi:10.1182/blood-2018-10-87964331101627
   PubMed Web of Science ®Google Scholar
• MenterT, HayozS, ZuccaE, KimbyE, DirnhoferS, TzankovA. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. Br J Haematol. 2020;190(4):e258–e261. doi:10.1111/bjh.1687632525232
   PubMed Web of Science ®Google Scholar
• MorschhauserF, FowlerNH, FeugierP, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Eng J Med. 2018;379(10):934–947. doi:10.1056/nejmoa1805104
   PubMed Web of Science ®Google Scholar
• Delfau-LarueMH, BoullandML, Beldi-FerchiouA, et al. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Adv. 2020;4(14):3217–3223. doi:10.1182/bloodadvances.202000195532673385
   PubMed Web of Science ®Google Scholar
• TuscanoJM, DutiaM, CheeK, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165(3):375–381. doi:10.1111/bjh.1275524606326
   PubMed Web of Science ®Google Scholar
• ChongEA, AhmadiT, AquiNA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21(8):1835–1842. doi:10.1158/1078-0432.CCR-14-222125632047
   PubMed Web of Science ®Google Scholar
• LeonardJP, JungSH, JohnsonJ, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635–3640. doi:10.1200/JCO.2014.59.925826304886
   PubMed Web of Science ®Google Scholar
• LeonardJP, TrnenyM, IzutsuK, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188.30897038
   PubMed Web of Science ®Google Scholar
• WitloxWJA, GrimmSE, RiemsmaR, et al. Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2021;39(2):171–180. doi:10.1007/s40273-020-00971-x33145711
   PubMed Web of Science ®Google Scholar
• AndorskyDJ, ColemanM, YacoubA, et al. MAGNIFY: phase IIIb interim analysis of induction R 2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(15_suppl):7513. doi:10.1200/jco.2019.37.15_suppl.7513
   Web of Science ®Google Scholar
• CheahCY, ChiharaD, AhmedM, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016;27(5):895–901. doi:10.1093/annonc/mdw02626802151
   PubMed Web of Science ®Google Scholar
• TillyH, MorschhauserF, CasasnovasO, et al. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 2018;5(9):e403–e410. doi:10.1016/S2352-3026(18)30131-530172345
   PubMed Web of Science ®Google Scholar
• StevensWBC, BakuninaK, CuijpersM, et al. HOVON110/ReBeL Study: results of the Phase I part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma. HemaSphere. 2020;4(1):e325. doi:10.1097/HS9.0000000000000325
   Web of Science ®Google Scholar
• RosenthalA, DueckAC, AnsellS, et al. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017;92(5):467–472. doi:10.1002/ajh.2469328230270
   PubMed Web of Science ®Google Scholar
• SmithSM, PitcherBN, JungSH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–e182. doi:10.1016/S2352-3026(17)30028-528314699
   PubMed Web of Science ®Google Scholar
• UjjaniCS, JungSH, PitcherB, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: alliance A051103. Blood. 2016;128(21):2510–2516. doi:10.1182/blood-2016-06-71810627697771
   PubMed Web of Science ®Google Scholar
• WangM, FowlerN, Wagner-BartakN, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902–1909. doi:10.1038/leu.2013.9523545991
   PubMed Web of Science ®Google Scholar
• YamshonS, ChristosPJ, DemetresM, HammadH, LeonardJP, RuanJ. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Adv. 2018;2(12):1429–1438. doi:10.1182/bloodadvances.201801668329934343
   PubMed Web of Science ®Google Scholar
• SuyamaT, YuiT, HoriuchiA, IrieR, OsamuraY, MiyaoN. Transient atelectasis due to hilar lymph node swelling affected by lenalidomide-induced tumor flare reaction. J Clin Exp Hematopathol. 2021;61(1):48–52. doi:10.3960/jslrt.20045
   Web of Science ®Google Scholar
• RummelMJ, Al-BatranSE, KimSZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(15):3383–3389. doi:10.1200/JCO.2005.08.10015908650
   PubMed Web of Science ®Google Scholar
• RobinsonKS, WilliamsME, van der JagtRH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(27):4473–4479. doi:10.1200/JCO.2008.17.000118626004
   PubMed Web of Science ®Google Scholar
• RummelMJ, NiederleN, MaschmeyerG, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi:10.1016/S0140-6736(12)61763-223433739
   PubMed Web of Science ®Google Scholar
• Solal-CeĺignyP, BelleiM, MarcheselliL, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–3853. doi:10.1200/JCO.2010.33.447423008294
   PubMed Web of Science ®Google Scholar
• TrotmanJ, FournierM, LamyT, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194–3200. doi:10.1200/JCO.2011.35.073621747087
   PubMed Web of Science ®Google Scholar